PHAR
NASDAQ
NL
Pharming Group N.V. - ADS, each representing 10 ordinary shares
$16.62
▼ $-0.30
(-1.77%)
Vol 42K
7
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$977.0M
P/E
11475.5
ROE
0.0%
Margin
0.0%
D/E
49.43
Beta
0.93
52W
$1–$2
Wall Street Consensus
14 analysts · Apr 20267
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.01 | $0.01 | $0.00 |
| Sep 2025 | $0.00 | $0.01 | +$0.01 |
| Jun 2025 | $-0.03 | $0.01 | +$0.03 |
| Mar 2025 | $-0.02 | $-0.02 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $92.7B | $79.1M | $93.2M | $97.3M | $106.5B |
| Net Income | — | $2.9B | -$14.7M | $4.7M | $7.5M | $5.3B |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -3.8% | -3.6% | -3.6% | -3.6% | 0.0% | 0.0% |
| P/E (TTM) | — | — | — | — | 10979.22 | 11475.46 |
| Net Margin | 5.0% | -2.4% | -2.4% | -2.4% | 0.0% | 0.0% |
| Gross Margin | 90.4% | 89.3% | 89.3% | 89.3% | 89.9% | 89.9% |
| D/E Ratio | 53.33 | 53.57 | 53.57 | 53.57 | 49.43 | 49.43 |
| Current Ratio | 2.80 | 2.79 | 2.79 | 2.79 | 3.16 | 3.16 |
Key Ratios
ROA (TTM)
0.0%
P/S (TTM)
3.17
P/B
3.3
EPS (TTM)
$0.00
CF/Share
$-0.01
Rev Growth 3Y
+14.3%
52W High
$1.53
52W Low
$0.66
$0.66
52-Week Range
$1.53
Financial Health
Free Cash Flow
$10.4M
Net Debt
-$29.5M
Cash
$145.3M
Total Debt
$115.8M
As of Dec 31, 2025
How does PHAR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
PHAR valuation vs Biotechnology peers
P/E ratio
11475.5
▲
61005%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.2
▼
75%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.3
▲
36%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
PHAR profitability vs Biotechnology peers
ROE
0.0%
▲
100%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
0.0%
▲
100%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
89.9%
▲
14%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
0.0%
▲
100%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
PHAR financial health vs Biotechnology peers
D/E ratio
49.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.2
▼
29%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.9
▼
5%
below
peers
(1.0)
vs Peers
vs Industry
Less volatile
PHAR fundamentals radar
PHAR
Peer median
Industry
PHAR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
PHAR vs peers: key metrics
Top Holders
Top 5: 0.19%Silverberg Bernstein Capita…
0.07%
$824K
NewEdge Advisors, LLC
0.04%
$471K
Millennium Management Llc
0.03%
$332K
Citadel Advisors Llc
0.03%
$289K
Smartharvest Portfolios, LLC
0.02%
$207K
As of Dec 31, 2025
Latest News
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 …
Yahoo Finance · Apr 04
Mirum Pharma (MIRM) Earnings Call Transcript
Yahoo Finance · Apr 03
Pharmaceuticals face 100% tariffs in US - unless firms strike a deal
BBC Business · Apr 03
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase …
Yahoo Finance · Apr 02
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Yahoo Finance · Apr 02